https://www.medscape.com/viewarticle/922885?

Appeals Court Rules ACA’s Individual Mandate Is Unconstitutional

Alicia Ault

December 18, 2019

A federal appeals court has ruled that the individual mandate of the Affordable Care Act (ACA) is unconstitutional, but the panel sent the case back to a lower court to decide how much of the remainder of the law could topple along with it.

The three-judge panel of the New Orleans-based US Fifth Circuit Court of Appeals said, “The individual mandate is unconstitutional because, under [a previous ruling, National Federation of Independent Business v Sebelius], it finds no constitutional footing in either the Interstate Commerce Clause or the Necessary and Proper Clause.”

The ruling upholds a December 2018 US District Court decision in which Judge Reed O’Connor found that the individual mandate that most Americans must have health insurance or pay a fine was unconstitutional, and that without it the ACA itself was invalid.

In sending the case back to a Texas district court, however, the federal panel is asking for a central question to be resolved: whether the individual mandate is “severable” from the rest of the law, leaving it intact.

If the district court eventually decides that the individual mandate cannot be severed from the rest of the ACA, the entire law will likely be ruled invalid, and some 24 million Americans could lose health coverage.

“Today’s ruling is the result of the Trump Administration and congressional Republicans attempting to make dangerous health policy using the courts since they failed to succeed in Congress,” House Ways and Means Committee Chairman Richard E. Neal (D-MA) said in a statement. “This is a blow to our nation’s health care system and the millions of Americans who have gained coverage and protections under the Affordable Care Act. Democrats will continue to fight to protect Americans’ access to quality, affordable care.”

Some groups are applauding the decision, though. The Citizens’ Council for Health Freedom (CCHF), which filed an amicus brief with the Fifth Circuit arguing against the ACA, said it wants more.

“We are pleased with the Fifth Circuit Court of Appeals ruling, but it didn’t go far enough,” said Twila Brase, president and cofounder of CCHF, in a statement. “The individual mandate cannot be severed from the rest of the 2,700-page Affordable Care Act, thus the court should have ruled that the entire law is invalid, as the lower district court found.

“As the Court notes in the first paragraph of the ruling, we argued in our Amicus Brief, filed jointly with the Association of American Physicians and Surgeons, that the Act ‘has deprived patients nationwide of a competitive market for affordable high-deductible health insurance,’ leaving ‘patients with no alternative to…skyrocketing premiums,’ ” Brase added. “Sending it back to the lower court, which already ruled the right way, continues to deprive citizens and patients of the affordable coverage that freedom from Obamacare would bring.”

Future Uncertain

The ruling in Texas v Azar is not a surprise, as during oral arguments in July, as reported by Medscape Medical News, at least two of the three judges — Jennifer Walker Elrod, appointed by President George W. Bush in 2007, and Kurt Engelhardt, appointed by President Donald J. Trump in 2018 — appeared to be more receptive to the arguments of a group of 18 Republican states and two individuals seeking to invalidate the ACA.

Judge Carolyn Dineen King, appointed by President Jimmy Carter in 1979, did not comment during the hearing.

The Trump administration chose not to defend the ACA, but it does not seem entirely prepared for what might happen if the law is overturned. In a briefing before the Fifth Circuit hearing, the administration argued that, if ultimately the law is ruled unconstitutional, it should be struck down only in the states seeking to overturn the law.

“A lot of this has to get sorted out — it’s complicated,” said August E. Flentje, a US Department of Justice lawyer, at the oral arguments in July.

For now, though, the ACA remains.

“In 2012, the Supreme Court upheld Obamacare, despite serious constitutional issues with the federal government forcing Americans to purchase a product from a private company. Until an ultimate decision is made by the Supreme Court or Congress decides otherwise, the Affordable Care Act will remain the law of the land,” Senate Finance Committee Chairman Chuck Grassley (R-IA), said in a statement.

And those who have led the court battle to keep the ACA intact plan to keep fighting. “For now, the President got the gift he wanted — uncertainty in the healthcare system and a pathway to repeal — so that the healthcare that seniors, workers and families secured under the Affordable Care Act can be yanked from under them. This decision could take us to a dangerous and irresponsible place, not just for the 133 million Americans with pre-existing conditions, but for our seniors who use Medicare, our children under the age of 26, and the 20 million additional Americans covered directly through the ACA marketplace. California will move swiftly to challenge this decision because this could mean the difference between life and death for so many Americans and their families,” California Attorney General Xavier Becerra said in a statement.

 

https://www.psychologytoday.com/us/blog/the-savvy-psychologist/201912/5-tips-calm-restless-mind-going-sleep?

5 Tips to Calm a Restless Mind Before Going to Sleep

If your mind won’t turn off at bedtime, use these tips to work with your brain.

Posted Dec 03, 2019

How did you sleep last night? We seem to ask ourselves this question daily, and when we do, it’s almost as if we’re taking note of our overall state of mind: How do I feel? Am I all there today?

And no wonder! It can be discouraging and frazzling when all we want is the soothing balm of sleep to heal the stress from our day, but infuriatingly, when we lie down to sleep, our brains just won’t shut off. Paradoxically, sometimes the more stressful our days are, the harder it is to quiet the brain for sleep at night…. (See link for full article)

________________

For more:  https://madisonarealymesupportgroup.com/2018/08/23/sleep-sweet-sleep/

https://madisonarealymesupportgroup.com/2018/04/02/cant-sleep-18-plants-herbs-can-help/

https://madisonarealymesupportgroup.com/2019/05/05/ambien-other-sleep-aids-get-fdas-blackbox-label-its-strongest-warning/

 

 

 

 

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/25452297?

Coming Soon: Human Testing Of Springtime Shot Against Lyme Disease

DEC 6, 2019 — 

Today’s letter to WBUR forwarded to the Tick-Borne Disease Working Group:

———- Original Message ———-

From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov
Cc: (98 Undisclosed recipients)
Date: December 6, 2019 at 9:50 AM
Subject: Coming Soon: Human Testing Of Springtime Shot Against Lyme Disease

To the Tick-Borne Disease working Group,

Please see the letter below addressed to Carey Goldberg, Editor, CommonHealth:
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: careyg@bu.edu
Cc: wburnews@wbur.org, info@wbur.org
Date: December 6, 2019 at 9:34 AM
Subject: Coming Soon: Human Testing Of Springtime Shot Against Lyme Disease

Coming Soon: Human Testing Of Springtime Shot Against Lyme Disease
https://www.wbur.org/commonhealth/2019/11/27/lyme-disease-shot-2020
November 27, 2019 By Carey Goldberg

Dec 6, 2019

WBUR
890 Commonwealth Avenue
Third Floor
Boston, MA  02215
Attn: Carey Goldberg, Editor, CommonHealth

Dear Ms. Goldberg,

In reference to the proposed shot against Lyme disease Klempner states: 

“The trial needs to be done in an area free of Lyme disease, so that it will be clear that antibodies in the blood come from the injection and not from previous exposure.” 

What will this “anti-Lyme injection” do to the individual who has been previously bitten and does not know he or she is living with an active Lyme infection?

Quote from a previous WBUR article titled: Antibody Shows Promise In Fight Against Lyme Disease, UMass Researcher Says
https://www.wbur.org/commonhealth/2019/05/03/antibody-lyme-disease-mice-research
May 03, 2019  By Colin A. Young

“It’s really based on some very simple notion that the bacteria, before it comes to you, is stuck in the gut of the tick” and must make a complex trip through the tick before it can infect a human, he said Thursday at a briefing. “Our approach is to take advantage of this very complicated pathway for the bacteria to get out of the tick and into you … a medicine that will circulate in you that when the tick drinks it, the blood will contain something that will kill the bacteria in the midgut or for sure prevent it from getting out of the gut so that none of this can happen.” 

Dr. Willy Burgdorfer (discoverer of the Borrelia burgdorferi spirochete) was quoted during a conference at Bard College in 1999 stating that about 5-10% of ticks that are carrying Lyme disease have a systemic infection and have the disease in their saliva and can transmit it as soon as they bite. He said,

“There is no safety window.”

What about all the other infections transmitted by a single tick bite; relapsing fever Borrelia, Babesia, Anaplasma, Ehrlichia, Bartonella, Rickettsia, Powassan and 230 more. The swamp will not be drained by this antibody approach and might even increase the risk because people start thinking they are protected which is not the case. 

The rush to create a vaccine for this “hard to catch and easily treated” [1] infection actually led to its mishandling as described in the following letter addressed to vaccinologist Dr. Stanley Plotkin:

Lemons and Lyme by Stanley Plotkin
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/23297377

The following letter sent to Dr. Klempner in April of 2018 deserves a second look:

Mark Klempner: Biowarfare Lab director NEIDL: National Emerging Infectious Disease Lab and CDC Biodefense Agent Lyme disease Guideline Author

———- Original Message ———-
From: Carl Tuttle <runagain@comcast.net>
To: mark.klempner@umassmed.edu
Cc: michael.collins@umassmed.edu, ddutko@hanszenlaporte.com, ryan.kantor@usdoj.gov, michelle.seltzer@usdoj.gov, william.rinner@usdoj.gov, makan.delrahim@usdoj.gov, tickbornedisease@hhs.gov, Elias, John, officeofthechancellor@umassmed.edu
Date: April 27, 2018 at 7:53 AM
Subject: Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease

April 27, 2018

University of Massachusetts Medical School
55 Lake Avenue North
Worcester, Massachusetts 01655
Attn: Mark S. Klempner, MD, Executive Vice Chancellor, MassBiologics

Dr. Klempner,

I would like to call attention to the attached study recently identifying chronic Lyme disease in twelve patients from Canada.

Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
http://www.mdpi.com/2227-9032/6/2/33

All of these patients were culture positive for infection (genital secretions, skin “Morgellons” and blood) even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.

In contrast, your 2001 antibiotic treatment study found; “no evidence of B. burgdorferi in a total of more than 700 different blood and cerebrospinal fluid samples from the 129 patients in these studies.”

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of LymeDisease http://www.nejm.org/doi/full/10.1056/NEJM200107123450202#article_references#t=references

Not a single positive Dr. Klempner? Doesn’t this statistically prove that your methodology was fatally flawed?

Did you culture skin and genital secretions as the Middelveen paper reports? It would appear that you conveniently stopped looking after your results supported the existing thirty year dogma; chronic Lyme does not exist.

Persistent Lyme disease is not new and has been intentionally/deceitfully suppressed for decades as described in the Vicki Logan case identified in the following letter to past CDC Director Barbara Fitzgerald:

https://www.dropbox.com/s/xaul84dqmqgbre0/Brenda%20Fitzgerald%20MD%20Director%20CDC.docx?dl=0

In 1991 B. burgdorferi had been isolated in culture from Vicki Logan’s CSF (CDC’s laboratory in Fort Collins CO.) despite prior treatment with 21 days of IV cefotaxime and 4 months of oral minocycline. 

The dishonest science here in the U.S. has denied chronic Lyme which stifled research to find a curative approach. Now the rest of the world is suffering.

We have lost nearly four decades to this 21st century plague due to the racketeering scheme identified in the RICO lawsuit filed by SHRADER & ASSOCIATES, LLP against the Infectious Disease Society of America, seven IDSA Panelists and eight insurance companies. The U.S. Centers for Disease Control has aligned itself with the seven IDSA Panelists identified in this lawsuit.

Court Document:
https://www.dropbox.com/s/18uyrli878ug51m/LymeDisease%20RICO%20Lawsuit.pdf?dl=0

Lyme is an incurable disease when not treated immediately which is spreading across North America and deceitfully misclassified as a low-risk and non-urgent health issue. Patient experience is describing a disease that is destroying lives, ending careers, causing death and disability while leaving victims in financial ruin. Current antimicrobials are ineffective for eradicating all forms of the Borrelia spirochete.

Public outcry has been ignored for decades while the Centers for Disease Control sat on evidence that this infection was not easily treated with a one size fits all treatment approach as dictated by the Infectious Diseases Society of America.

Once again your studies were fatally flawed while supporting the controlling dogma leaving hundreds of thousands if not millions worldwide with a persistent infection and absolutely no relief. We have another AIDS on our hands. 

Carl Tuttle

Independent Researcher
Lyme Endemic Hudson, NH

Cc: -Michael F. Collins, Chancellor
-The Tick Borne Disease Working Group
-US Department of Justice
-Daniel R. Dutko, HANSZEN LAPORTE

REFERENCE:

1. Lyme Disease Is Hard to Catch And Easy to Halt, Study Finds
New York Times By GINA KOLATA Published: June 13, 2001
http://www.nytimes.com/2001/06/13/us/lyme-disease-is-hard-to-catch-and-easy-to-halt-study-finds.html

Click here to support My Dad Carl Tuttle Needs Help to Overcome Lymphoma organized by Erika Tuttle
My Dad, Carl Tuttle, is in a battle to overcome lymphoma. He has a very good chance to succeed and have many more years of life, but…
____________________
https://madisonarealymesupportgroup.com/2017/09/07/20268/  New Lyme Vaccine Coming Soon: Caveat Emptor – Buyer Beware!

https://www.ncbi.nlm.nih.gov/pubmed/31745036

2019 Apr-Jun;37(2):292-295. doi: 10.4103/ijmm.IJMM_19_4.

Multifocal hepatic abscesses in immunocompetent patient due to Bartonella henselae: Case report with review of literature.

Abstract

To the best of our knowledge, this is the first case of multifocal hepatic abscesses in a young immunocompetent adult from India, which was successfully treated with hepatectomy and short course of oral antibiotic regimen. Publishing further such case reports will provide more clarity regarding the clinical significance of the disease, including associated risk factors and appropriate treatment.

________________

**Comment**

Hepatic abscesses, like abscesses elsewhere, are localized collections of necrotic inflammatory tissue caused by bacterial, parasitic or fungal agents. In this case, Bartonella.  Multifocal just means the abscesses are in more than one location.

For more:  https://madisonarealymesupportgroup.com/2019/11/27/development-spontaneous-resolution-of-a-full-thickness-macular-hole-in-bartonella-neuroretinitis/

 

 

 

https://globallymealliance.org/risk-benefit-analysis-of-tick-borne-disease-treatments/

image of the word risk

by Jennifer Crystal

ASKING IMPORTANT QUESTIONS WHEN IT COMES TO LYME TREATMENT. DO THE BENEFITS OUTWEIGH THE RISKS?

At the 2019 International Lyme and Associated Diseases Society (ILADS) conference in Boston, there was a lot of buzz about two up-and-coming Lyme treatments: Disulfiram and Dapsone. Both medications have shown powerful efficacy against Lyme, and Disulfiram may also treat babesia. Learning of the success stories of late-stage Lyme patients who have taken these medications—subsequently enjoying remissions of six months or more—makes many people want to run out and try them. I am among them.

However, like most medications, these drugs also come with risks. Both can cause strong Herxheimer reactions, especially if taken at too high a dose too quickly. Disulfiram, more commonly known as Antabuse, a drug used to treat alcoholism, causes a severe reaction if the patient comes in contact with alcohol. And not just from having taken a sip of a drink; the slightest contact with alcohol-based lotions, hand sanitizers, mouthwashes, shampoos, or other products can make the patient vomit and feel extremely hungover. More rarely, the drug may cause psychosis.

If I were bedridden with tick-borne illnesses, as I once was, I would be eager to try one of these medications. At that time I was so sick I would have tried anything. My head throbbed with migraines; I was plagued with insomnia, and when I did sleep, I had hallucinogenic nightmares. I felt tied to my bed as if by the world’s worst case of flu. This went on for years. Eventually, antibiotic and antimalarial treatments, combined with nutritional supplements and adjunct therapies like neurofeedback and integrative manual therapy, helped me into remission. After one serious relapse, I have stayed in remission for over a decade, seeing steady improvements.

At 80% of restored health, I am living a good life. I can work part-time, write, socialize, and exercise. However, I also still have to stick to a strict sleep schedule; I still have to take low-dose antibiotics and other medications, and I still have to take a nap every afternoon. As I listened to doctors talk about  Disulfiram and Dapsone at the ILADS conference, I wondered, “Could one of those medicines help me get even better? Could it eliminate my afternoon nap, or reduce my reliance on antibiotics?”

I asked one of the panelists, a Lyme Literate Medical Doctor (LLMD), this very question. “Let’s say a patient was at 80% restored health after years of battling tick-borne disease,” I said, explaining all the things this hypothetical patient could and could not do. “Is that a case in which you would prescribe Disulfiram or Dapsone, or are those medications better for someone in the acute stages of the illness?”

“That’s up to the patient,” the doctor replied. “Are they satisfied with their 80% lifestyle? Are they willing to feel terrible when they’re on the medication in order to feel better afterward? It’s really a question of risk-benefit analysis.”

This was a term I’d heard in my early days of Lyme treatment, and one I wrestled with many times as I tried new protocols. At each juncture, I had to consider, do the risks of taking this medication outweigh the benefits or vice-versa? For example, when I started taking sleep medication, I worried that I would become addicted. My doctor reasoned, “But you aren’t sleeping. You can’t get well without sleep. So the benefit of the medication outweighs the risk.”

I also did a cost-benefit analysis years ago when I was trying to decide if I should continue with oral antibiotics or try intravenous antibiotics through a Peripherally Inserted Central Catheter (PICC). My doctor said that intravenous antibiotics would get at the infection faster, and would take the pressure off my gut, since oral antibiotics come with their own adverse side effects, intestinal yeast overgrowth among them. I was managing that risk with a specialized diet and probiotics, but intravenous antibiotics would help.

However, intravenous antibiotics also came with risks. Herxheimer reactions could be more severe. The PICC line could clot. I had to be very careful not to get it wet, or water could go in the line, to my heart. Moreover, the specific intravenous antibiotic my doctor recommended could, in rare cases, cause gallstones.

At that point in my journey, I was so sick that I wanted to try the strongest, fastest course of action possible. To me, the possible benefits of intravenous antibiotics outweighed the risks, so I made the choice to get a PICC line.

My Herxheimer reactions were indeed severe. My line did clot once, and a nurse had to make an emergency visit to my home to fix it. As if that weren’t enough downside, I also developed gallstones and had to have my gallbladder removed (Note: Not all intravenous antibiotics have this side effect, and there are now medications to help counter it). Despite these complications, the PICC line helped move me towards remission within a year, so I feel the treatment was worth it.

Now that I’m doing well, my view of the risks and benefits of new medications is different. If I were still as sick as I once was, I absolutely would try Disulfiram or Dapsone. But in my current life, I can’t take time off to battle severe Herxheimer reactions, nor do I want to. I don’t want to run the risk of losing the gains I’ve earned. I’d love to give up my afternoon nap, but I’m not currently willing to feel worse in order to possibly make that happen, especially with no guarantee. I certainly don’t want to get to a point where I say, “Remember when I was doing so well that all I had to do was take an afternoon nap?”

For now, I’m content making smaller tweaks to my treatment protocol such as adding supplements and lowering antibiotic doses that might improve my energy. The risks of these moves are relatively low. At some point, I may want to take a larger leap. After more research is done on Disulfiram and Dapsone, I may decide their benefits do indeed outweigh their risks and try one of them.

Another patient in my shoes might feel differently. They might be willing to possibly go back to 50% if that meant they could get 100% wellness eventually. I respect that. The bottom line is that you have to do what’s right for your body, and you and your LLMDneed to weigh the risks and benefits of choices for your specific case. At the end of the day, you’re the one living with Lyme disease and possibly other tick-borne infections, so you get to decide what risks you do and don’t want to take.


jennifer crystal_2

Opinions expressed by contributors are their own.

Jennifer Crystal is a writer and educator in Boston. Her memoir about her medical journey is forthcoming. Contact her at lymewarriorjennifercrystal@gmail.com.

 

 

___________________

Perfectly stated!